title: Clinical results of drug eluting stents compared to bare metal stents for patients with ST elevation acute myocardial infarction.
abstract: OBJECTIVE
  To investigate the clinical outcomes in patients with ST segment elevation acute myocardial infarction (STEMI) treated with drug eluting stents (DES) versus a matched control group of patients with STEMI treated with bare metal stents (BMS).
  
  
  METHODS
  This registry included 122 patients with STEMI undergoing primary coronary angioplasty with DES implantation at our institution. The control group consisted of 506 patients implanted with BMS, who were matched for age, infarct location, and diabetic status. The incidences of major adverse cardiac events (MACE) including target vessel/lesion revascularization (TVR/TLR) and stent thrombosis were assessed up to 12 months.
  
  
  RESULTS
  Twelve months follow up showed a non-significant trend towards reduced deaths (3.3% versus 7.1%, P=0.1), significantly reduced recurrent MI (0.0% versus 6.1%, P=0.02), TVR (5.7% versus 15.2%, P=0.006) and TLR (2.5% versus 14.0%, P=0.004) events in the DES group as compared to BMS group. The composite incidences of MACE at 12 months follow-up was lower in the DES group (11.5%) as compared to the BMS group (21.3%, P=0.01).
  
  
  CONCLUSIONS
  According to our experiences, the use of DES in STEMI is safe and effective as compared to BMS. DES was effective in reducing the incidence of restenosis outcomes and overall adverse cardiac events up to 12 months.
authors.affiliation: Cardiology Department, Rabin Medical Center, Petah-Tikva, The 'Sackler' Faculty of Medicine, Tel-Aviv University, Israel. rkornowski@clalit.org.il
authors.forename: R
authors.initials: R
authors.lastname: Kornowski
authors.forename: H
authors.initials: H
authors.lastname: Vaknin-Assa
authors.forename: E
authors.initials: E
authors.lastname: Lev
authors.forename: I
authors.initials: I
authors.lastname: Ben-Dor
authors.forename: I
authors.initials: I
authors.lastname: Teplitsky
authors.forename: E
authors.initials: E
authors.lastname: Rechavia
authors.forename: D
authors.initials: D
authors.lastname: Brosh
authors.forename: S
authors.initials: S
authors.lastname: Fuchs
authors.forename: A
authors.initials: A
authors.lastname: Assali
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000628:therapy*; D017239:Paclitaxel / Q000008:administration & dosage; D012042:Registries; D012189:Retrospective Studies; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives; D015607:Stents
chemical_list: D007166:Immunosuppressive Agents; C489443:zotarolimus; D017239:Paclitaxel; D020123:Sirolimus